Cerebral venous thrombosis (CVT) is a rare but important complication after COVID-19.
1,2 In a prospective study involving 47 572 patients with COVID-19, 4 young patients (aged 27 to 38 years) were diagnosed with CVT,
3 and CVT occurred more often in COVID-19 infection than the general population.
4 More recently, as vaccination against SARS-CoV-2 is used as a public health measure against the COVID-19 pandemic,
5 CVT has been reported following vaccination, mostly with the adenovirus vector-based vaccines (Ad26.COV2.S [Janssen/Johnson & Johnson]
6 and ChAdOx1-S [Oxford-AstraZeneca]
7). CVT after messenger RNA (mRNA)-based vaccines has been reported
8,9 but data from observational cohorts have yet to show an increased incidence.
10,11 Hence it currently remains unclear if CVT is indeed associated with mRNA-based SARS-CoV-2 vaccines.